Article
TGA Transparency reforms (part 1): Notification of generic and biosimilar medicines to impact pharmaceutical patent disputes in Australia
Recent regulatory changes are likely to impact the way that pharmaceutical patent litigation is conducted in Australia.
Spruson & Ferguson Lawyers

